The Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors

Launched by HUBEI CANCER HOSPITAL · Feb 1, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at the risk factors for a condition called acute radiation pneumonitis in cancer patients who have previously received a type of treatment known as immune checkpoint inhibitors (ICIs). Acute radiation pneumonitis is a lung condition that can occur after radiation therapy, and the researchers want to understand what makes some patients more likely to experience this problem.

To be eligible for the trial, participants need to have a confirmed cancer diagnosis and must have received ICIs before undergoing a specific type of radiation therapy called thoracic intensity-modulated radiotherapy, which targets tumors in the chest area. The study is currently recruiting patients of all ages and genders. Those who participate will help researchers gather important information that may improve treatment and care for future cancer patients. It’s a chance to contribute to understanding how different treatments can affect lung health after radiation therapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Pathologically or cytologically confirmed malignant tumor
• • 2. Cancer patients with previously received ICIs underwent thoracic intensity-modulated radiotherapy
• Exclusion Criteria:
• • 1. Cancer patients did not receive immunotherapy before thoracic intensity-modulated radiotherapy
• • 2. Non-thoracic radiotherapy patients